RxDoctor Payments Data

Sulaiman Tijani, MD

Pulmonary Disease · Danville, VANPI 1255852018

Payments from drug & device makers

$5,157in general payments, 2019–2025

Across 107 payments — averaging $48.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$1K
  • Olympus Corporation Of The Americas$1K
  • AstraZeneca$551
  • Noah Medical Corporation$504
  • GSK$315
  • Sanofi$251
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$2,68552%
  • Food & beverage$2,46348%
  • Education$90%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,157 in reported general payments places this provider in the 60th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$74,550
Medicare patients
188
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$84,399
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$17,337
Breo ElliptaFluticasone/Vilanterol33$12,195
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$12,076
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,618
Bevespi AerosphereGlycopyrrolate/Formoterol Fum16$8,254
Spiriva RespimatTiotropium Bromide14$7,280
Wixela InhubFluticasone Propion/Salmeterol15$1,230
Albuterol Sulfate HfaAlbuterol Sulfate46$874
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$873
Fluticasone Propionate17$164
Montelukast Sodium29$145
Prednisone72$111
Pantoprazole Sodium14$92
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$315$105,212171 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$551$25,59040 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$30$19,35635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →